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Summary
NF-B is a transcription factor that can protect from or contribute to apoptosis. Here we report identification of HSCO
that binds to NF-B and inhibits apoptosis. HSCO mRNA was overexpressed in 20 of 30 hepatocellular carcinomas analyzed.
Overexpression of HSCO inhibited caspase 9 activation and apoptosis induced by DNA damaging agents, while it augmented
apoptosis induced by TNF. Like IB, HSCO inhibited NF-B activity and abrogated p53-induced apoptosis. However,
the underlying mechanism was different. HSCO is a nuclear-cytoplasmic shuttling protein, bound to RelA NF-B, and HSCO
sequestered it in the cytoplasm by accelerating its export from the nucleus. These results suggest that overexpression of
HSCO suppresses p53-induced apoptosis by preventing nuclear localization of NF-B during signaling and thus contributes
to hepatocarcinogenesis.
Introduction which have distinct affinities for DNA target sites. The most
abundant forms are RelA-p50 heterodimers and RelA-RelA
One of the most frequent carcinomas throughout the world homodimers. The NF-B/Rel family plays major roles in the
is hepatocellular carcinoma (HCC) (Murray and Lopez, 1997; inducible expression of a large number of genes involved in
Hamilton and Aaltonen, 2000). HCC is rapidly fatal, with a life inflammation, host defense, cell survival, and proliferation. NF-
expectancy of about 6 months from time of diagnosis. The B is one of the key proteins that modulates the apoptotic
disease is more prevalent in parts of Africa and Asia than in response (Barkett and Gilmore, 1999; Karin and Lin, 2002). The
North and South America and Europe, with a strong etiological rela knockout mouse dies in utero as a result of massive liver
association with viral hepatitis, hemochromatosis, known car- apoptosis (Beg et al., 1995). Fibroblasts established from rela
cinogens, and toxins. In areas where exposure to aflatoxin B1 is knockout mice show increased sensitivity to tumor necrosis
prevalent, mutation of the p53 gene, one of the most commonly
factor  (TNF)-induced apoptosis, and RelA expression re-
mutated genes identified in various types of human cancers
verses their sensitivity to TNF in these cells (Beg and Baltimore,(Vogelstein et al., 2000), is observed in 50%–67% of HCCs
1996). The accumulating data have suggested a role for NF-B(Tannapfel and Wittekind, 2002). In areas such as Japan, Eu-
in the prevention of apoptosis. However, under some circum-rope, and USA, however, p53 mutation is not frequent, espe-
stances, activation of NF-B is required for apoptosis (Barkettcially in low-grade or low-stage HCCs (Konishi et al., 1993). To
and Gilmore, 1999). For example, Dengue virus-infected HepG2date, many genes have been shown to be altered in HCCs, but
hepatocytes undergo apoptosis in vitro, and treatment of thesethe molecular mechanisms of hepatocarcinogenesis have not
cells with NF-B decoys inhibits the virally induced cell deathbeen fully elucidated (Feitelson et al., 2002).
(Marianneau et al., 1997). Ryan et al. (2000) have shown thatThe vertebrate NF-B/Rel family of transcription factors in-
NF-B activation is required for p53-mediated apoptosis andcludes five members: RelA (p65), RelB, c-Rel, NF-B1(p105)/
that rela/ mouse embryonic fibroblasts are resistant to p53-p50, and NF-B2(p100)/p52 (Baldwin, 1996; Pahl, 1999). These
can form most combinations of homodimers or heterodimers, induced cell death. Depending on a variety of circumstances,
S I G N I F I C A N C E
Although there are many modalities of treatment for hepatocellular carcinoma (HCC), the prognosis is unsatisfactory. We identified
a novel phylogenetically conserved protein, HSCO, that is overexpressed in a substantial number of human HCCs and so is likely
to have relevance to clinical cancers. A function for HSCO was identified in the cytoplasmic sequestration of RelA NF-B, resulting
in the inhibition of p53-mediated apoptosis. Thus, HSCO is a promising target for HCC treatment, especially in combination with
DNA-damaging agents. The present study will contribute to the development of therapeutic strategies to repair the apoptotic p53
response in cancers.
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Figure 1. Identification of HSCO and its relation
to glyoxalase II
A: Deduced amino acid sequence of human
HSCO and its alignment with those of human
glyoxalase II (accession number X90999), puta-
tive HSCOs in the mouse, Drosophila (AE003826),
C. elegans (Z68493), Arabidopsis (U74610), Sy-
nechocystis (D90909), and yeast GLO4
(CAA99230). Identical and conserved amino
acid residues are indicated by asterisks and dots,
respectively. The human and mouse sequence
data are available from GenBank/EMBL/DDBJ
under accession number D83198 and AB049623,
respectively. B: No glyoxalase II activity detected
in HSCO. Left: GST-HSCO, GST-human glyoxalase
II (GLXII), and GST alone were purified from bac-
terial lysates with glutathione beads. Parts of the
samples were separated by SDS-PAGE and
stained with silver. Lanes 2, 4, and 7: purified sam-
ples; lanes 3 and 5: lysates; lanes 1 and 6: molec-
ular weight markers. Right: Glyoxalase II activity
in purified proteins.
including the cell type and the inducing agent, NF-B complexes Results and Discussion
seem to have pro- or antiapoptic effects.
Identification of HSCO, a novel glyoxalase II-relatedTo identify genes involved in hepatocarcinogenesis and find
protein overexpressed in HCC cellstargets for therapeutic agents, we have constructed subtracted
One of the clones overexpressed in HCC encoded a novel pro-cDNA libraries enriched for the genes overexpressed in HCCs,
tein, which we named HSCO (Hepatoma Subtracted-cDNA li-and previously identified gankyrin (Higashitsuji et al., 2000).
brary Clone One). The amino acid sequence of HSCO showed
Gankyrin is an oncogenic ankyrin-repeat protein, was overex-
similarity to that of human glyoxalase II, but was more similar
pressed in all examined HCCs, and accelerates the degradation to those of putative HSCO homologs in the mouse, Drosophila,
of the retinoblastoma gene product (Rb). Here we report the C. elegans, Arabidopsis, Synechocystis, and yeast GLO4 (Figure
identification and characterization of HSCO. HSCO bound to 1A). In Arabidopsis thaliana, five isozymes are known for glyoxa-
NF-B, accelerated its export from the nucleus, and inhibited lase II, and HSCO showed strongest homology to GLX2-3 in
amino acid sequence. HSCO contained a metallo--lactamase-p53-mediated apoptosis.
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like region that encompasses between 35 and 196 in amino acid
sequence. This metallo--lactamase-like region is conserved
within the related proteins, and a consensus sequence of
HXHXD(X)iH(X)jC(X)kH (in single-letter code for amino acids
where X indicates any amino acid and i  55–74, j  18–24,
and k  37–41) conserved throughout this family is believed to
be the Zn(II) ligands (Daiyasu et al., 2001; Zang et al., 2001).
The N-terminal and C-terminal extensions have no homology
to known proteins.
In biological systems, methylglyoxal is detoxified to S-D-
lactoylglutathione by glyoxalase I with reduced glutathione as
a cofactor, and S-D-lactoylglutathione is converted to D-lactic
acid by glyoxalase II with simultaneous regeneration of glutathi-
one (Zang et al., 2001). Glyoxalase I is selectively overexpressed
in some human tumor cells and can function as a resistance
factor to antitumor agent-induced apoptosis (Sakamoto et al.,
2000). The target(s) of glyoxalase I responsible for induction of
apoptosis has not been identified. Because of a suggested key
role of glyoxalase system to detoxify cytotoxic methylglyoxal in
tumor cells and a structural similarity of HSCO to glyoxalase II,
we analyzed the glyoxalase II activity of HSCO in vitro. As shown
in Figure 1B, the control GST-glyoxalase II fusion protein
showed the expected enzymatic activity. However, HSCO did
not show any activity, indicating that HSCO is a phylogenetically
conserved protein related to but distinct from glyoxalase II.
Possible enzymatic activity of HSCO and its substrates are yet
to be determined.
The mRNA level of HSCO was increased between 155%
and 1198% (mean, 332%) in 20 of 30 HCCs studied (Figure 2A
and data not shown). As shown in Figure 2B, HSCO encoded
protein of about 27 kDa in size, and its expression was increased
in HCCs compared with those in noncancerous liver tissues.
Immunohistochemical analysis revealed that HSCO protein lo-
calized mainly in the cytoplasm of tumor cells (Figure 2C). We
next examined the relation between the overexpression of
Figure 2. Increased expression of HSCO in hepatocellular carcinoma (HCC)HSCO and the clinicopathological findings such as virus infec-
cells
tion, -fetoprotein, histologic grade of HCC, portal involvement,
A: Increased expression of HSCO mRNA in HCCs. Total RNA from five pairs
number of tumors, and clinical stage, but no significant associa- of HCCs (1T to 5T) and noncancerous liver tissues (1N to 5N) were analyzed
tion was identified (data not shown). by Northern blotting using human HSCO (top) or 18S rRNA (bottom) cDNA
as a probe. An arrow indicates the mobility of HSCO mRNA. B: Expression
of HSCO protein in HCCs. Cell lysates from three pairs of HCCs (2T, 6T, 7T)Resistance to p53-dependent apoptosis,
and noncancerous liver tissues (2N, 6N, 7N) were analyzed by Westernbut sensitization to TNF-induced
blotting using an anti-HSCO antibody (top) or anti-actin antibody (bottom).
apoptosis conferred by HSCO C: Expression of HSCO protein in tumor cells. Immunohistochemical staining
To elucidate the role(s) played by HSCO in hepatocarcinogen- of HCC thin sections was performed using anti-HSCO antibody (left) or
normal rabbit IgG (right). The bound antibody was visualized using diamino-esis, we stably overexpressed HSCO in mouse NIH/3T3 fibro-
benzidine as a substrate. The bar equals 50 m.blasts to the level almost equivalent to those observed in HCCs
(Figure 3A). No changes in cellular morphology, population dou-
bling times, or anchorage-dependent growth appeared in the
clones analyzed (data not shown).
cells to apoptosis induced by TNF (Figure 3B). Several studiesUsing these stable transfectants, we explored an involve-
have demonstrated that NF-B plays a critical role in the modi-ment of HSCO in apoptosis. Antitumor agents and TNF were
fication of cellular sensitivity to TNF-mediated killing (Liu et al.,used to induce p53-dependent and p53-independent apo-
1996; Beg and Baltimore, 1996). TNF sensitivity is also shownptoses, respectively (Evan and Vousden, 2001; Johnstone et
to be regulated by oncogenes and viral infection (Perez andal., 2002). The NIH/3T3 cells overexpressing HSCO were more
White, 2000; You et al., 2002). To exclude a possibility that theresistant to adriamycin and etoposide compared with vector-
observed findings were due to clonal differences of transfec-transfected control cells (Figure 3B). The p53 protein levels were
tants rather than overexpression of HSCO, we generated thecomparable between these cells (data not shown). The activity
HeLa Tet-On-HSCO cells in which HA-tagged HSCO is ex-of caspase 9 induced by etoposide in HSCO-overexpressing
pressed at a level equivalent to those observed in HCCs onlycells was 21%  3% of that induced in control cells (n  3,
in the presence of doxycycline (Dox) (Figure 3C). Similar to theeach), consistent with a notion that HSCO conferred resistance
to p53-dependent apoptosis. By contrast, HSCO sensitized the findings in NIH/3T3 transfectants, HSCO conferred resistance
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Figure 3. Differential effects of HSCO on apoptosis induced by antitumor agents and TNF
A and B: Effects of stably overexpressed HSCO on apoptosis in NIH/3T3 transfectants. HSCO protein levels in two clones each of NIH/3T3 transfectants stably
overexpressing HSCO (lanes 3 and 4) and vector-transfected control (lanes 1 and 2) and HCC (lane 5) were analyzed by Western blotting using anti-HSCO
antibody (A). Two clones each of NIH/3T3 trnsfectants overexpressing HSCO (,	) and control (,) were exposed to adriamycin (left), etoposide (middle),
or TNF with cycloheximide (right), and the surviving cell numbers were estimated by MTT assay (B). C and D: Effects of inducibly expressed HSCO on
apoptosis in HeLa cells. C: HSCO protein levels in HCC (lane 1) and two HeLa Tet-On-HSCO clones (lanes 2 to 5 are from one clone) cultured with () or
without () doxycycline (Dox) were analyzed by Western blotting using anti-HSCO, anti-HA, or anti-actin antibody as indicated. D: HeLa Tet-On-HSCO
clones cultured in the presence (, 	) or absence (,) of Dox were assayed as in B. E and F: Effects of reduced HSCO level on apoptosis in HeLa cells.
E: HSCO mRNA and protein levels in HeLa cells transfected with pSUPER-HSCOwt (lanes 2 and 4) or pSUPER-HSCOmut (lanes 1 and 3) that contain sequences
derived from wild-type or mutant HSCO cDNA, respectively, were analyzed by Northern (lanes 1 and 2) and Western (lanes 3 and 4) blottings using cDNA
probes and antibodies as indicated. F: HeLa cells cultured in the presence of pSUPER-HSCOwt (	) or pSUPER-HSCOmut () were assayed as in B.
to apoptosis induced by adriamycin and etoposide, while it observed on sensitivity to TNF (Figure 3F). Essentially similar
results were obtained with human HCC cell lines, Huh-7 andsensitized the cells to apoptosis induced by TNF (Figure 3D).
Recently, efficient and specific downregulation of gene ex- PLC/PRF/5, using siRNAs or oligoDNAs antisense to HSCO
transcripts (data not shown). The reason why the decrease inpression has been achieved by using small interfering RNAs
(siRNAs) in mammalian cells (Brummelkamp et al., 2002). To the level of HSCO did not result in a decrease in sensitivity to
TNF is presently unknown, but one possibility may be thataddress the questions of how general the effect of HSCO on
apoptotic sensitivity is and how relevant it is to HCCs that during establishment and/or maintenance of cancer cell lines,
those that have lost the increase in TNF sensitivity had advan-overexpress HSCO, we inhibited the expression of HSCO by
siRNAs and assessed the changes in sensitivity to apoptosis. tage and predominated the culture.
Recently, NF-B has been shown to be essential for p53-As shown in Figure 3E, siRNAs successfully decreased the level
of endogenous HSCO protein in HeLa cells. These cells were induced apoptosis (Ryan et al., 2000). To assess the effects
of HSCO on this NF-B-dependent apoptosis, we engineeredmore sensitive to apoptosis induced by adriamycin and etopo-
side compared with control HeLa cells, while no effect was Saos-2 cells, a tumor cell line that does not express endogenous
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Figure 4. Effect of HSCO on NF-B-mediated
apoptosis in Saos-2 cells
A: Expression of p53 in Saos-2 Tet-On-p53 cells
in the presence (), but not absence (), of
doxycycline (Dox) detected by Western blot
analysis using anti-p53 (top) and anti-actin (bot-
tom) antibodies. B: Apoptosis of Saos-2 Tet-On-
p53 cells induced in the presence (	), but not
absence (), of Dox. C: Abrogation of p53-
induced apoptosis by HSCO. Saos-2 Tet-On-p53
cells were transfected with plasmid encoding
HSCO (), SRIB (), or empty vector (	) and
cultured in the presence of Dox. The numbers of
surviving cells were counted as indicated. Data
represent the average of triplicates  S.D. Three
independently established Saos-2 Tet-On-p53
cell clones gave similar results, and representa-
tive results are shown.
p53, to inducibly express wild-type p53 (Figure 4A). As reported of NF-B activation (Spitkovsky et al., 2002). The suppressive
effects of HSCO on NF-B activation, however, did not seemby Ryan et al. (2000), induction of p53 in these cells led to
apoptosis (Figure 4B), which was abrogated by expression of to be mediated by IB, because HSCO did not affect its amount
or phosphorylation status after stimulation with TNF or etopo-super-repressor IB (SRIB), which completely inhibits NF-
B activity (Figure 4C; Brockman et al., 1995). HSCO abrogated side (Figure 6A). By immunoprecipitation analysis, no complex
formation was demonstrated between HSCO and IB (datathe apoptosis induced by expression of p53 in these cells as
efficiently as SRIB (Figure 4C). Western blot analysis showed not shown).
As HSCO showed an activity similar to SRIB (Figure 4C),that expression of SRIB or HSCO had no effect on the level
of p53 protein (data not shown). Taken together, these results we suspected that HSCO might bind to NF-B. To investigate
this possibility, we used the HeLa Tet-On-HSCO cells in whichdemonstrated that HSCO confers resistance to antitumor agent-
induced, p53-dependent apoptosis, but sensitizes to TNF- HSCO is expressed in the presence of Dox (Figure 3C). After
stimulation with TNF or etoposide and only in the presence ofinduced apoptosis in HCC and other cell lines, and suggest
that HSCO has a suppressive effect on NF-B activity. They Dox, HA-HSCO was coimmunoprecipitated with endogenous
RelA by anti-RelA antibody (Figure 6B, top). We did not observealso suggest that HSCO may be related to resistance of HCC
to chemotherapy. the coimmunoprecipitation with anti-c-Rel nor anti-p50 anti-
body (data not shown). In a reciprocal experiment, we detected
RelA, but not c-Rel or p50, in the immune complex precipitatedSuppressive effect of HSCO on NF-B activity and its
interaction with RelA/p65 but not IkB by anti-HA antibody (Figure 6B, bottom, and data not shown).
We obtained similar results using the 293 cells expressing theWe, therefore, examined the effect of HSCO on the transactiva-
tion activity of NF-B. After serum withdrawal, luciferase activity exogenous RelA and HA-HSCO (data not shown). The interac-
tion between endogenous HSCO and RelA was also observedwas induced in 293 cells transfected with an NF-B-dependent
luciferase reporter construct (Figure 5A). HSCO dose-depen- in HeLa cells after stimulation with etoposide (Figure 6C). These
dently suppressed this transactivation. HSCO suppressed the results demonstrated that the overexpressed endogenous
NF-B activities induced by MEKK and RelA/p65 subunit of NF- HSCO and RelA specifically interacts in human tumor cells.
B as well (Figures 5B and 5C). These effects were specific to The interaction was further analyzed by the in vitro protein
NF-B because HSCO did not affect AP-1 activity nor E2F-1 binding assay. We prepared recombinant wild-type HSCO pro-
activity (Figure 5D and data not shown). Although HSCO has a tein fused to glutathione-S-transferase (GST). The GST-HSCO
structural similarity to glyoxalase II (Figure 1), expression of fusion protein pulled down the in vitro translated full-length RelA
glyoxalase II had no effect on the transactivation activity of NF- (Figure 6D). No interaction of RelA was observed with the control
B (Figure 5E). We further confirmed the suppressive effect of GST protein. Analysis of various mutant RelA proteins demon-
HSCO on NF-B activity by decreasing its endogenous level. strated that the HSCO-interacting domain resided in residues 1
In HeLa cells, the HSCO protein levels were decreased by trans- to 300 of RelA (Figure 6D), indicating that the nuclear localization
fection with either pSUPER plasmid that generates siRNAs or signal (NLS) of RelA is not involved in this interaction.
oligoDNAs antisense to HSCO transcripts (Figure 3E and data
not shown). As shown in Figure 5F, when HSCO level was Decreased activity and amount of nuclear NF-B
in HSCO-overexpressing cells caused by itsdecreased, the etoposide-induced NF-B activity was in-
creased in them. accelerated export from the nucleus
To clarify the mechanisms by which HSCO inhibits the activityThe activity of NF-B is known to be regulated by IB
(Karin and Lin, 2002). Activation of NF-B occurs after the disso- of NF-B, we analyzed the effect of HSCO on NF-B DNA
binding activity by the electrophoretic mobility shift assayciation of the cytoplasmic NF-B-IB complex, which is pre-
ceded by the phosphorylation of IB. Human papilloma virus (EMSA) (Figure 7A). Treatment of 293 cells with etoposide in-
duced an elevation of NF-B DNA binding activity in the nuclearoncoprotein E7 targets the IB kinase complex and impairs
IB phophorylation and degradation, resulting in attenuation extracts. Cotransfection of HSCO cDNA in expression vector
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Figure 5. Inhibitory effect of HSCO on NF-B ac-
tivity
A: Effect on NF-B activity induced by serum star-
vation. 293 cells were cotransfected with NF-B-
responsive luciferase reporter and plasmids ex-
pressing HA-tagged HSCO (HSCO) and HA alone
(vector) as indicated. Cells were subjected to
32 hr of serum deprivation, and then luciferase
activity was determined. B and C: Effects on NF-
B activity induced by overexpression of MEKK
or RelA. 293 cells were transfected with plasmids
expressing MEKK (pFC-MEKK) or RelA (pCMV-
RelA) together with NF-B-responsive reporter
and plasmids expressing HA-HSCO as indicated.
Luciferase activities were determined 48 hr after
transfection. D: No effect of HSCO on AP-1 activ-
ity. 293 cells were cotransfected with AP-1-
responsive luciferase reporter and plasmids ex-
pressing HA-HSCO as indicated E: No effect of
human glyoxalase II on NF-B activity. 293 cells
were cotransfected with pCMV-RelA and NF-B-
responsive reporter together with plasmids ex-
pressing HA-glyoxalase II (GLXII) and HA alone
(vector) as indicated. Luciferase activities were
determined 48 hr after transfection. F: Increased
NF-B activity induced by decreased HSCO ex-
pression. HeLa cells were cotransfected with the
reporter plasmid and either oligoDNAs
(ASN-control and ASN-HSCO, control and anti-
sense to HSCO, respectively) or pSUPER con-
structs (pSUPER-HSCOmut and pSUPER-HSCOwt,
siRNA-nonproducing and siRNA-producing con-
structs, respectively), then treated with etopo-
side and analyzed as above. The values are
expressed as percentage to those in vector-
transfected controls. Data represent the aver-
age of triplicates  S.D.
dose-dependently decreased the amount of nuclear NF-B spe- B sites and in vitro translated RelA were incubated with increas-
ing amounts of GST-IB, the amount of bound NF-B wascifically bound to the DNA probe. The specificity of the band
was confirmed by its disappearance with 100-fold excess of decreased. By contrast, GST-HSCO up to 10 times molar ex-
cess to RelA had no effect on the complex formation betweenunlabeled wild-type B oligonucleotides but not with those mu-
tated in the B binding site. The supershift assay using anti- RelA and B sites. However, when RelA and GST-HSCO were
first incubated for 30 min and then radiolabeled B sites wereRelA, anti-p50, or anti-cRel antibody indicated that the induced
protein-DNA complex mainly composed of RelA-RelA homodi- added, HSCO dose-dependently decreased the amount of
RelA-RelA homodimer bound to the B sites (Figure 7C). GST-mers. These results indicated that the DNA binding activity and/
or the amount of nuclear NF-B is decreased by overexpression glyoxalase II showed no such effect. These results demon-
strated that HSCO binds to RelA and partially prevents it fromof HSCO.
We therefore examined the effect of HSCO on the DNA binding to the B sites, but this effect is weak compared with
that of IB, and HSCO cannot dissociate RelA from the boundbinding activity of NF-B in vitro (Figure 7B). When radiolabeled
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Figure 6. Interaction of HSCO with RelA in vitro
and in vivo
A: No effect of HSCO on the amount and phos-
phorylation of IB protein. HeLa Tet-On-HSCO
cells were cultured in the presence () or ab-
sence () of doxycycline (Dox) as indicated.
They were then treated with vehicle alone (lane
1), TNF (lanes 2 and 3), or etoposide (lanes 4
and 5). Nuclear extracts (top two gels) or whole
cell lysates (bottom four gels) were prepared
and analyzed by Western blotting using anti-
RelA, anti-histone H3, anti-IB, anti-phospho-
IB (Ser32/36), anti-HA, and anti-actin antibod-
ies as indicated. B: Interaction of inducibly over-
expressed HSCO with RelA in vivo. HeLa Tet-On-
HSCO cells were cultured in the presence () or
absence () of Dox as indicated. They were then
treated with TNF (lanes 1, 2, 5, and 6) or etopo-
side (lanes 3, 4, 7, and 8), and lysates were pre-
pared from them. 5% of the input lysates (lanes
5 to 8) and one-quarter of immune complexes
precipitated by anti-RelA antibody (top, lanes 1
to 4) or anti-HA antibody (bottom, lanes 1 to 4)
were analyzed by Western blotting using anti-
HA or anti-RelA antibody as indicated. Arrows
indicate mobilities of the HA-HSCO (top) and en-
dogenous RelA (bottom). C: Interaction of en-
dogenous HSCO with endogenous RelA in vivo.
HeLa cells were cultured in the presence (lanes
2, 3, 5, and 6) or absence (lanes 1 and 4) of
etoposide, and lysates were prepared from
them. One-quarter of immune complexes pre-
cipitated by anti-RelA antibody (lanes 1 and 2)
or anti-HSCO antibody (lanes 4 and 5), and 10%
of the input lysates (lanes 3 and 6) were analyzed
by Western blotting using anti-HSCO or anti-RelA
antibody as indicated. D: Interaction of HSCO
with RelA in vitro. Top: Schematic representation
of RelA (full) and its mutants (del-1 to -4). The
numbers above the bar indicate the amino acid
residue numbers in wild-type RelA. Black boxes,
nuclear localization signal; shaded boxes, Rel-
homology domain. Bottom: Interaction of HSCO
with the amino terminus of RelA. 35S-labeled wild-type RelA (full) or its deletion mutants (del-1, del-3, and other data not shown) were incubated with
glutathione beads containing GST-HSCO fusion protein (lanes 1) or GST alone (lanes 2). Specifically bound proteins were resolved by SDS-PAGE and
autoradiography. One-tenth of the input were run in parallel (lanes 3). Arrows indicate mobilities of the expected recombinant proteins.
B sites. We next examined the amount of RelA in the nucleus COS7, HeLa, and 293 cells, but did not observe accumulation
of the mutant proteins in the nucleus (Hiroaki Higashitsuji andof cells overexpressing HSCO. As shown in Figure 7D, expres-
sion of HSCO dose-dependently decreased the amount of nu- J.F., unpublished). Thus, the identity of the nuclear export signal
is presently unknown.clear NF-B. Recently, c-myc has been shown to sensitize cells
to TNF-mediated apoptosis by interfering with RelA transactiva- When 293 cells were transfected with plasmids expressing
RelA, RelA accumulated in the nucleus (Figure 8B, top). Aftertion but not nuclear translocation of NF-B (You et al., 2002).
By contrast, HSCO sensitized cells to TNF-mediated apoptosis cotransfection with HSCO expressing plasmid, however, RelA
colocalized with HSCO and was sequestered in the cytoplasmby interfering with nuclear accumulation of RelA.
Immunohistochemical analysis suggested that HSCO local- (Figure 8B, middle). This is consistent with the above finding
that expression of HSCO dose-dependently decreased theized mainly in the cytoplasm of HCC cells (Figure 2C). As shown
in Figure 8A, HSCO was diffusely present in the cytoplasm and amount of nuclear NF-B (Figure 7D). In the presence of lepto-
mycin B, both HSCO and RelA mainly localized in the nucleusnucleus in HeLa cells. In the presence of leptomycin B, a nuclear
export inhibitor that disrupts the interaction between CRM1/ (Figure 8B, bottom), indicating that HSCO does not inhibit nu-
clear translocation of RelA, but stimulates its export from theexportin 1 and nuclear export signal (Kudo et al., 1999), HSCO
accumulated in the nucleus, indicating that HSCO is a nuclear- nucleus. The effect of HSCO on RelA was specific because it
showed no effect on the localization of a nuclear-cytoplasmiccytoplasmic shuttling protein. In the amino acid sequence of
HSCO, there are several regions rich in leucine and possibly shuttling protein CIRP (Nishiyama et al., 1998) (data not shown).
By treating HeLa Tet-On HSCO cells with TNF, we also ob-acting as the nuclear export signal (Figure 1A). We made five
different double mutants, i.e., 24A/25A, 68A/70A, 70A/72L, served that HSCO caused the cytoplasmic accumulation of
endogenous RelA during signaling (Figure 8C). To assess215A/217A, and 229A/231A, of HSCO and expressed each in
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Figure 7. Decreased activity and amount of nuclear NF-B in cells overexpressing HSCO
A: Inhibition of etoposide-induced nuclear NF-B DNA binding activity by HSCO in vivo. Equal amounts (10 g) of nuclear extracts were subjected to
electrophoretic mobility shift assays (EMSAs) with a radiolabeled consensus kB site oligoDNAs. 293 cells were transfected with plasmids expressing HA alone
or HA-tagged HSCO as indicated and were treated with etoposide (lanes 3 to 14), and nuclear lysates were prepared from them. For competition analysis,
a 100-fold excess of unlabeled wild-type (lane 5) or mutant (lane 6) kB site oligoDNAs were added to the reaction mixture. For supershift assays, nuclear
extracts were incubated with 1 g of antibody as indicated (lanes 7 to 10). Mobilities of the NF-kB specific complex and supershifted complex are indicated
by arrows. Comparability of the various nuclear extracts was verified by EMSA with a radiolabeled Sp1 probe (data not shown). B: Dissociation of RelA
from bound DNA induced by IB but not by HSCO in vitro. Radiolabeled B probe was preincubated with RelA, and then increasing amounts (molar ratio
to RelA, 1:0, 1:2, and 1:10) of GST-IB, GST-HSCO, or GST-glyoxalase II (GLXII) were added to the reaction mixtures as indicated. They were analyzed after
further incubation. C: Inhibition of RelA binding to DNA by preincubation with HSCO. In vitro EMSA was done as described for B, except that RelA and GST-
HSCO or GST-GLXII were preincubated for 30 min at 25
C and then mixed with radiolabeled B site probe. In some reactions, nonradiolabeled wild-type
or mutant B competitors or antibodies were added as indicated. D: Decreased amount of nuclear RelA induced by HSCO. 293 cells were cotransfected
with plasmids expressing RelA, HSCO, or none (vector) as indicated. The nuclear extracts (top two gels) and whole cell extracts (bottom) were analyzed
by Western blotting using anti-RelA antibody (top and bottom) or anti-SC35 antibody (middle).
whether the overexpressed endogenous HSCO observed in cytoplsmic shuttling protein. Recently, IB has also been
shown to shuttle between nucleus and cytoplasm (Arenzana-HCC cells functions to sequester endogenous RelA as in trans-
fected cells, we treated a human HCC cell line, Huh-7, that Seisdedos et al., 1997; Johnson et al., 1999; Tam et al., 2000;
Carlotti et al., 2000). Chen et al. (2001) has further demonstratedoverexpresses HSCO with TNFor etoposide and then analyzed
the localization of RelA. RelA was not translocated to the nucleus that RelA is subject to inducible acetylation in the nucleus, and
the acetylated form interacts weakly, if at all, with IB. It isof Huh-7 cells after stimulation (data not shown). Similar results
were obtained when Huh-7 cells were transfected with pSUPER postulated that after acting as a transcription factor, acetylated
RelA is deacetylated, binds to IB, and is exported from thevector that does not produce siRNA and treated with etoposide
(Figure 8D, top). However, when expression of HSCO was sup- nucleus. Since HSCO is mainly bound to the nonacetylated form
of RelA (Hiroaki Higashitsuji and J.F., unpublished) and HSCOpressed with siRNA, RelA accumulated in the nucleus (Figure
8D, bottom), indicating that overexpressed endogenous HSCO did not dissociate RelA once it bound to DNA, HSCO probably
binds RelA in the nucleus before it is acetylated and exports itsequestered RelA in the cytoplasm in human HCC cells.
The traditional model postulates that, in unstimulated cells, to the cytoplasm through a CRM-1-dependent pathway, re-
sulting in inhibition of NF-B activity.NF-B is sequestered in the cytoplasm in an inactive form bound
to an inhibitory IB protein (Foo and Nolan, 1999; Ghosh et al., Several oncoproteins such as human papilloma virus E6
and E7 (Spitkovsky et al., 2002) and c-Myc (You et al., 2002) have1998; Cyert, 2001). IB binds to and hides the NLS of RelA.
Upon stimulation, IB is rapidly phosphorylated, ubiquitinated, been shown to inhibit NF-B activity by various mechanisms. In
the present study we have demonstrated that overexpressedand subsequently degraded by the proteasome. This releases
NF-B, allowing it to translocate to the nucleus, where it can HSCO shows antiapoptotic activity by inhibiting NF-B activity.
Although NF-B in most situations shows antiapoptotic activi-induce the expression of a diverse array of genes. We found
that HSCO did not affect IB, but did affect NF-B activity. ties, it also has proapoptotic activities (Barkett and Gilmore,
1999; Ryan et al., 2000). Furthermore, Gapuzan et al. (2002)We found that HSCO binds to RelA subunit of NF-B and causes
its localization in the cytoplasm. However, the NLS of RelA was has recently shown that RelA has tumor-suppressing activity.
We have also demonstrated that the expression of HSCO wasnot involved in the binding. By using leptomycin B, we showed
that the accelerated export from, rather than decreased translo- increased in 67% of HCCs examined and that the overex-
pressed endogenous HSCO confers resistance to p53-depen-cation into, the nucleus is the cause of the observed cytoplasmic
accumulation of RelA. We demonstrated that HSCO is a nuclear- dent apoptosis induced by adriamycin and etoposide in HCC
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Figure 8. HSCO-induced cytoplasmic sequestration of NF-B due to accelerated export from the nucleus
A: Nuclear-cytoplasmic shuttling of HSCO. HeLa cells were cultured in the presence () or absence () of leptomycin B (LMB) and analyzed by confocal
microscopy after staining with rabbit anti-HSCO antibody and FITC-conjugated secondary antibody. Blue signals indicate localization of nucleus stained
with DAPI. B: Cytoplasmic sequestration of exogenous RelA by overexpression of HSCO. COS-7 cells were transfected with RelA cDNA alone (top) or in
combination with HSCO cDNA (middle and bottom). They were then cultured in the presence () or absence () of LMB and analyzed by confocal
microscopy after staining with anti-HSCO antibody, anti-RelA antibody, respective secondary antibody, and DAPI. Red, green, and blue signals indicate
the localization of HSCO, RelA, and the nucleus, respectively. Yellow signals (merge) indicate colocalization of HSCO and RelA. C: Cytoplasmic sequestration
of endogenous RelA in cells overexpressing HSCO. HeLa Tet-On HSCO cells were cultured in the presence () or absence () of doxycycline (Dox), treated
with TNF, and then analyzed by confocal microscopy after staining with anti-HSCO and anti-RelA antibodies as described in B. D: Cytoplasmic sequestration
of endogenous RelA in HCC cells and its correction by siRNA. Huh-7 cells overexpressing HSCO were transfected with pSUPER-HSCOwt that produces siRNA
specific to HSCO or pSUPER-HSCOmut that does not produce siRNA. They were stimulated with etoposide and then analyzed by confocal microscopy
after staining with anti-HSCO and anti-RelA antibodies and DAPI as described in B.
and uterine cancer cell lines. HCC has been regarded as a tumor are expected to retain wild-type p53 (Konishi et al., 1993) with
increased expression of HSCO suppressing, at least partially,quite resistant to chemotherapeutic agents (Treiber, 2001). In
one study, of the 21 patients treated with etoposide, only 1 its proapoptotic activity. By inhibiting HSCO and repairing the
apoptotic p53 response in these HCCs, we may be able toshowed a partial response. Monochemotherapy has yielded
unsatisfactory results with response rates of around 20% but design effective therapeutic interventions. Further studies on
the regulation and function of HSCO will contribute to the under-survival is often not improved. Polychemotherapies may have
standing of molecular mechanism of hepatocarcinogenesis andsomewhat higher response rates, but with substantial side ef-
development of therapeutic strategies against HCCs.fects. The most common antiapoptotic lesion that is detected
in cancers is inactivation of the p53 tumor-suppressor pathway
Experimental procedures(Vousden and Lu, 2002). Mutations within the TP53 gene (which
encodes p53) itself are found in about half of all cancers, but
Cell culture
often at a rather late stage in malignant development. At presen- NIH/3T3, COS-7, 293, Saos-2, HeLa, Huh-7, and PLC/PRF/5 cells and their
tation, most cancers have lost p53 function by one mechanism derivatives were maintained in Dulbecco’s modified Eagle medium supple-
mented with 10% fetal bovine serum at 37
C in a humidified atmosphere ofor another, and in HCCs, especially those at early stages, many
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5% CO2 in air. For induction of apoptosis, cells were treated with etoposide assay, HSCO cDNA was cloned into the expression vector pGEX-4T (Amer-
sham Pharmacia Biotechnology, Tokyo, Japan) and expressed as GST-(100 g/ml), adriamycin (0.5 g/ml), or TNF (50 ng/ml)  cycloheximide
(10 g/ml). In serum deprivation experiment, 293 cells were cultured in HSCO fusion protein. 35S-labeled RelA and its mutant proteins were prepared
by using a TNT Trascription/Translation System (Promega, Madison, Wis-medium without fetal bovine serum for 32 hr. The plasmid expressing SRIB
was a kind gift from Dr. D.W. Ballard, Nashville, TN. Transfection and isolation consin) and assayed as described (Higashitsuji et al., 2000).
of stable clones were performed as described (Higashitsuji et al., 2000).
293 and NIH/3T3 cell clones stably expressing HSCO were obtained by Electrophoretic mobility shift assay (EMSA)
transfecting the cells with pMKit-Neo-HSCO plasmids containing HSCO 293 cells were transfected with plasmids, and 24 hr later the nuclear extracts
cDNA. As a control, vector alone was transfected. Saos-2 Tet-On-p53 cells were prepared as described by Schreiber et al. (1989). Binding reactions were
were made by cotransfection of Saos-2 cells with pTet-On plasmid and performed by adding 10 g of the nuclear extracts to a mixture containing 0.1
ng of 32P-labeled, double-stranded B site oligoDNAs (wild-type B site, 5-pTRE2 plasmid (Clontech, Tokyo, Japan) containing p53 cDNA, followed by
AGTTGAGGGGACTTTCCCAGGC-3; mutant B site with G to C substitutionselection of clones inducibly overexpressing p53. Similarly, 293 Tet-On-
in the Rel DNA binding domain, 5-AGTTGAGGCGACTTTCCCAGGC-3) inHSCO cells and HeLa Tet-On-HSCO cells were made by transfecting 293
20 l of binding buffer (10 mM Tris [pH 7.5], 10 mM EDTA, 0.5 mM DTT,cells and HeLa cells, respectively, with pTet-On plasmid and pTRE2 plasmid
50 mM NaCl, and 5% glycerol) containing 10 g of bovine serum albumincontaining HA-tagged HSCO cDNA. Numbers of viable cells were counted
and 2 g of poly(dI-dC):poly(dI-dC). For supershift experiments, 1 g ofby the trypan blue dye exclusion method using a hemocytometer under a
antibody directed against RelA, p50, c-Rel, or Sp-1 (Santa Cruz) was addedmicroscope or estimated by the MTT assay.
to aliquots of extract and incubated for 30 min on ice before addition of theFor production of siRNA in the cells, we made the pSUPER vector
reaction mixture. Competition reaction mixtures contained a 100-fold molarcontaining the polymerase-III H1-RNA gene promoter and the gene-specific
excess of nonradioactive B sites.insert that specifies a 19 nt sequence derived from the target transcript,
For in vitro EMSA, human RelA protein was produced in vitro by usingseparated by a short spacer (9 nt long) from the reverse complement of the
a TNT Transcription/Translation System (Promega) as above. Human IB,same 19 nt sequence as described by Brummelkamp et al. (2002). pSUPER-
HSCO, and glyoxalase II cDNAs were introduced into pGEX4T vector seriesHSCOwt contained the 19 nt derived from the HSCO cDNA (nt number 393
(Amersham Pharmacia), and each GST fusion protein was purified accordingto 411, GenBank accession number D83198) as the target sequnce. As a
to the manufacturer protocol. The nonradiolabeled consensus and mutantcontrol, we made pSUPER-HSCOmut containing mutations at HSCO cDNA
B oligoDNAs were used in competition assays. Antibodies were added tont numbers 406 (A to G) and 408 (A to C). The sequence of the oligo DNA
an EMSA reaction mixture in a supershift assay as above. A dissociationantisense to HSCO mRNA was derived from the cDNA nt number 55 to 74.
assay was performed by preincubating RelA with radiolabeled B probe forScrambled 20-mer oligoDNA served as a control.
15 min at 25
C, followed by addition of 1:2 or 1:10 of GST-IB, GST-HSCO,
or GST-glyoxalase II. The mixtures were incubated for 15 min at 25
C.cDNA cloning and analysis of gene expression
Another in vitro RelA EMSA study was performed by preincubating RelAPairs of primary HCCs and noncancerous liver tissues were obtained from
with GST-IB, GST-HSCO, or GST-glyoxalase II for 30 min at 25
C, andpatients undergoing surgery at Kyoto University Hospital. Informed consent
then B probe was added. The mixtures were further incubated for 15 minwas obtained from all patients. cDNA subtraction, cDNA cloning, and nucleo-
at 25
C. Free and bound DNAs were separated by electrophoresis in atide sequence analysis have been described (Higashitsuji et al., 2000). Immu-
nondenaturing 4% polyacrylamide gel. Gels were dried and exposed to filmnohistochemistry and Western and Northern blot analyses were performed
at 80
C with an intensifying screen.as described (Danno et al., 2000). An anti-HSCO polyclonal antibody was
produced by immunizing rabbits with a carboxy-terminal oligopeptide
Assay for glyoxalase II activity(NMRCGVQTPTA). For fractionation experiments, cytoplasmic extracts were
GST-glyoxalase II fusion protein and GST-HSCO fusion protein were pre-prepared by lysis of cells in hypotonic buffer containing protease inhibitors
pared as described above using plasmids containing full-length human gly-and a mixture of phosphatase inhibitors. Nuclear extracts were prepared by
oxalase II cDNA and HSCO cDNA, respectively. Glyoxalase II activity wasplasma membrane permeabilization in hypotonic buffer containing 0.5 mM
assayed by measuring the initial rate of hydrolysis of S-D-lactoylglutathioneDTT, 10 mM HEPES (pH 8.0), 10 mM KCl, and 1.5 mM MgCl2. Nuclei were
to GSH and D-lactic acid as described by Di Ilio et al. (1995). The assaythen lysed in hypertonic buffer containing 20 mM HEPES (pH 8.0), 420 mM
solution contained 0.5 mM Tris-HCl buffer (pH 7.5), 300 M of S-D-lactoyl-NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25% (v/v) glycerol, 0.5 mM DTT, and
glutathione, and appropriate amounts of purified proteins. Glyoxalase II fromprotease inhibitors. Cytoplasmic and nuclear extracts were analyzed by
bovine liver (Sigma) and GST alone served as a positive and negative control,Western blotting using rabbit anti-IB (Santa Cruz Biotechnology, Santa
respectively.Cruz, CA), anti-histone H3 (Santa Cruz), goat anti-p65/RelA (Santa Cruz),
anti-actin (Santa Cruz), mouse anti-SC35 (Sigma Aldrich Japan, Tokyo, Ja-
pan), anti-phopho-IB (Ser32/36) (Cell Signaling Tech., Beverly, MA), and Reporter gene assay
Luciferase reporter vectors containing NF-B binding sites (pNF-B-Luc)mouse anti-HA (Roche Diagnostics, Tokyo, Japan) antibodies. Caspase-9
activity was measured by the Caspase calorimetric protease assay kit (MBL, or AP-1 binding sites (pAP-1-Luc) in the promoter were purchased from
Stratagene (La Jolla, CA). The luciferase reporter vector containing E2F-1Nagoya, Japan) following the manufacturer’s protocol.
binding sites was provided by Dr. A. Harel-Bellan, Centre National de la
Recherche Scientifique, France. The reporter plasmid and pRL-TK (Promega)Analysis of protein-protein interactions
were cotransfected with increasing amounts of HSCO cDNA in expressionHeLa Tet-On-HSCO cells were cultured in the presence or absence of Dox.
vector pCMV4-3HA with or without pFC-MEKK, pCMV-RelA, or pCMV-GLXIIEndogenous RelA NF-B activity was induced by incubating these cells with
expressing human glyoxalase II, into 293 cells by the calcium phosphateTNF (50 ng/ml) for 1 hr or etoposide (50 g/ml) for 4 hr. Then cell lysates
method. After 48 hr, cells were lysed and luciferase activity was measuredwere prepared, and immunoprecipitation and Western blot analysis were
by a Dual luciferase assay system (Promega) following the manufacturer’sperformed using goat or rabbit anti-RelA; rabbit anti-cRel, anti-p50, anti-
protocol. Effects of HSCO on endogenous RelA activity were also analyzedIB, and anti-HSCO; and mouse anti-RelA and anti-HA antibodies as de-
using 293 cells cotransfected with the reporter plasmid, pRL-TK, and in-scribed (Higashitsuji et al., 2000). To analyze interaction between endoge-
creasing amounts of HSCO cDNA as above and then cultured without serum.nous HSCO and endogenous RelA, HeLa cells were treated with etoposide,
To analyze the effects of decreasing the HSCO protein level, HeLa cellsand cell lysates were immunoprecipitated using rabbit anti-HSCO or goat
were cotransfected with the reporter plasmid, pRL-TK, and either oligoDNAsanti-RelA antibody immobilized to the protein G support (Seize X Mammalian
or pSUPER constructs, then treated with etoposide and analyzed as above.Immunoprecipitation Kit, Pierce, Rockford, IL), followed by Western blot
analysis. Interaction of exogenous RelA with HSCO was examined by
cotransfecting 293 cells with plasmid pCMV-RelA (Yang et al., 1999), kindly Immunofluorescence staining
Cells were replated on chamber slides after transfection and cultured in theprovided by Dr. T. Okamoto, Nagoya, Japan, and HA-tagged HSCO cDNA
or HA cDNA in pCMV4 expression vector. Then, immunoprecipitation and presence or absence of leptomycin B (2 ng/ml) kindly provided by Dr. M.
Yoshida, Tokyo, Japan. For some experiments, Dox, TNF, etoposide, orWestern blot analysis were performed as above. For the GST pull-down
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Evan, G.I., and Vousden, K.H. (2001). Proliferation, cell cycle and apoptosisvehicle alone were added to the culture with or without transfection. The
in cancer. Nature 411, 342–348.cells were fixed with PBS containing 4% paraformaldehyde for 30 min, then
rendered permeable with PBS containing 0.2% Triton X-100 for 30 min at Feitelson, M.A., Sun, B., Satiroglu Tufan, N.L., Liu, J., Pan, J., and Lian, Z.
room temperature. After blocking nonspecific antibody binding sites with (2002). Genetic mechanisms of hepatocarcinogenesis. Oncogene 21, 2593–
bovine serum albumin, the cells were incubated with a rabbit anti-HSCO 2604.
and/or a mouse anti-RelA antibodies. Bound antibodies were detected with
Foo, S.Y., and Nolan, G.P. (1999). NF-B to the rescue: RELs, apoptosisa goat anti-rabbit secondary antibody conjugated to TRITC or FITC (Dako
and cellular transformation. Trends Genet. 15, 229–235.Japan, Kyoto, Japan) and a sheep anti-mouse secondary antibody conju-
gated to FITC (BD PharMingen, San Diego, CA) and viewed under a confocal Gapuzan, M.E., Yufit, P.V., and Gilmore, T.D. (2002). Immortalized embryonic
microscope (Olympus, Tokyo, Japan). Chromosomal DNA was visualized mouse fibroblasts lacking the RelA subunit of transcription factor NF-kappaB
by staining with blue-fluorescent 4,6-diamidino-2-phenylindole (DAPI, Mo- have a malignantly transformed phenotype. Oncogene 21, 2489–2492.
lecular Probes, Inc., Eugene, OR).
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